Last reviewed · How we verify
Levalbuterol UDV TID
Levalbuterol is a selective beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing in patients with obstructive airway disease.
Levalbuterol is a selective beta-2 adrenergic agonist that relaxes airway smooth muscle to improve breathing in patients with obstructive airway disease. Used for Asthma maintenance and acute bronchospasm relief, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Levalbuterol UDV TID |
|---|---|
| Also known as | Xopenex Inhalation Solution |
| Sponsor | Sumitomo Pharma America, Inc. |
| Drug class | Beta-2 adrenergic agonist (short-acting) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Levalbuterol is the active R-enantiomer of albuterol that binds to beta-2 adrenergic receptors on airway smooth muscle cells, triggering intracellular signaling that increases cAMP levels and causes bronchodilation. The UDV (unit dose vial) formulation is administered via nebulizer three times daily (TID) for rapid onset of action in acute or maintenance therapy of asthma and COPD.
Approved indications
- Asthma maintenance and acute bronchospasm relief
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Nervousness
- Headache
- Palpitations
- Tachycardia
Key clinical trials
- A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma (PHASE3)
- Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |